Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

Purpose: We performed a phase I trial to investigate the safety, clinical responses, and Wilms' tumor 1 (WT1)-specific immune responses following treatment with dendritic cells (DC) pulsed with a mixture of three types of WT1 peptides, including both MHC class I and II–restricted epitopes, in combination with chemotherapy. Experimental Design: Ten stage IV patients with pancreatic ductal adenocarcinoma (PDA) and 1 patient with intrahepatic cholangiocarcinoma (ICC) who were HLA-positive for A*02:01, A*02:06, A*24:02, DRB1*04:05, DRB1*08:03, DRB1*15:01, DRB1*15:02, DPB1*05:01, or DPB1*09:01 were enrolled. The patients received one course of gemcitabine followed by biweekly intradermal vaccinations with mature DCs pulsed with MHC class I (DC/WT1-I; 2 PDA and 1 ICC), II (DC/WT1-II; 1 PDA), or I/II–restricted WT1 peptides (DC/WT1-I/II; 7 PDA), and gemcitabine. Results: The combination therapy was well tolerated. WT1-specific IFNγ-producing CD4+ T cells were significantly increased following treatment with DC/WT1-I/II. WT1 peptide-specific delayed-type hypersensitivity (DTH) was detected in 4 of the 7 patients with PDA vaccinated with DC/WT1-I/II and in 0 of the 3 patients with PDA vaccinated with DC/WT1-I or DC/WT1-II. The WT1-specific DTH-positive patients showed significantly improved overall survival (OS) and progression-free survival (PFS) compared with the negative control patients. In particular, all 3 patients with PDA with strong DTH reactions had a median OS of 717 days. Conclusions: The activation of WT1-specific immune responses by DC/WT1-I/II combined with chemotherapy may be associated with disease stability in advanced pancreatic cancer. Clin Cancer Res; 20(16); 4228–39. ©2014 AACR.

[1]  Y. Takeda,et al.  Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.

[2]  C. Craddock,et al.  Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses , 2013, British journal of haematology.

[3]  L. Terracciano,et al.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. , 2013, European journal of cancer.

[4]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Z. Berneman,et al.  Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes , 2013, Leukemia.

[6]  L. Zitvogel,et al.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.

[7]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[8]  Y. Yonemitsu,et al.  Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma , 2012, Pancreas.

[9]  H. Arakawa,et al.  Current Immunotherapeutic Approaches in Pancreatic Cancer , 2011, Clinical & developmental immunology.

[10]  H. Tajiri,et al.  Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response , 2011, Cancer Immunology, Immunotherapy.

[11]  G. Gaudernack,et al.  Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras , 2011, International journal of cancer.

[12]  V. Huff,et al.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene , 2011, Nature Reviews Cancer.

[13]  H. Ueno,et al.  Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer , 2011, Journal of immunotherapy.

[14]  M. Moore,et al.  Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.

[15]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[16]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[17]  I. Kawase,et al.  A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells , 2008, Microbiology and immunology.

[18]  C. Figdor,et al.  Dendritic cell vaccination and immune monitoring , 2008, Cancer Immunology, Immunotherapy.

[19]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[20]  D. Scheinberg,et al.  Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells , 2007, Clinical Cancer Research.

[21]  I. Kawase,et al.  Identification and Characterization of a WT1 (Wilms Tumor Gene) Protein-derived HLA-DRB1*0405-restricted 16-mer Helper Peptide That Promotes the Induction and Activation of WT1-specific Cytotoxic T Lymphocytes , 2007, Journal of immunotherapy.

[22]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[23]  C. Figdor,et al.  Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Khorana,et al.  Pancreatic cancer and thromboembolic disease. , 2004, The Lancet. Oncology.

[25]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Monden,et al.  Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma , 2004, Cancer science.

[27]  D. Sawyer,et al.  Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion1 , 2004, The Journal of Immunology.

[28]  I. Kawase,et al.  Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.

[29]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[30]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[31]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[32]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[33]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[34]  M. Oster.  Thrombophlebitis and Cancer , 1976, Angiology.

[35]  Karen Margolis,et al.  Disclosure of Potential Conflicts of Interest , 2014 .

[36]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[37]  R. Schreiber,et al.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.